Tichelbäcker, Tobias

[["dc.bibliographiccitation.firstpage","335"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","340"],["dc.bibliographiccitation.volume","207"],["dc.contributor.author","Kefer, Joelle"],["dc.contributor.author","Tzikas, Apostolos"],["dc.contributor.author","Freixa, Xavier"],["dc.contributor.author","Shakir, Samera"],["dc.contributor.author","Gafoor, Sameer"],["dc.contributor.author","Nielsen-Kudsk, Jens Erik"],["dc.contributor.author","Berti, Sergio"],["dc.contributor.author","Santoro, Gennaro"],["dc.contributor.author","Aminian, Adel"],["dc.contributor.author","Landmesser, Ulf"],["dc.contributor.author","Nietlispach, Fabian"],["dc.contributor.author","Ibrahim, Reda"],["dc.contributor.author","Danna, Paolo Luciano"],["dc.contributor.author","Benit, Edouard"],["dc.contributor.author","Budts, Werner"],["dc.contributor.author","Stammen, Francis"],["dc.contributor.author","De Potter, Tom"],["dc.contributor.author","Tichelbaecker, Tobias"],["dc.contributor.author","Gloekler, Steffen"],["dc.contributor.author","Kanagaratnam, Prapa"],["dc.contributor.author","Costa, Marco"],["dc.contributor.author","Cruz-Gonzalez, Ignacio"],["dc.contributor.author","Sievert, Horst"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Park, Jai-Wun"],["dc.contributor.author","Meier, Bernhard"],["dc.contributor.author","Omran, Heyder"],["dc.date.accessioned","2018-11-07T10:16:50Z"],["dc.date.available","2018-11-07T10:16:50Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Left atrial appendage occlusion (LAAO) using the Amplatzer cardiac plug (ACP) is a preventive treatment of atrial fibrillation related thromboembolism. Aim: To assess the safety and efficacy of LAAO in patients with chronic kidney disease (CKD). Methods: Among the ACP multicentre registry, 1014 patients (75 +/- 8 yrs) with available renal function were included. Results: Patients with CKD (N = 375, CHA2DS2-VASc: 4.9 +/- 1.5, HASBLED: 3.4 +/- 1.3) were at higher risk than patients without CKD (N = 639, CHA2DS2-VASc: 4.2 +/- 1.6, HASBLED: 2.9 +/- 1.2; p < 0.001 for both). Procedural (97%) and occlusion (99%) success were similarly high in all stages of CKD. Peri-procedural major adverse events (MAE) were observed in 5.1% of patients, 0.8% of death, with no difference between patients with and those without CKD (6.1 vs 4.5%, p = 0.47). In patients with complete follow-up (1319 patients years), the annual stroke + transient ischaemic attack (TIA) rate was 2.3% and the observed bleeding rate was 2.1% (62 and 60% less than expected, similarly among patients with and those without CKD). Kaplan-Meier analysis showed a lower overall survival (84 vs 96% and 84 vs 93% at 1 and 2 yrs. respectively; p < 0.001) among patients with an eGFR <30 ml/min/1.73 m(2). Conclusion: LAAO using the ACP has a similar procedural safety among CKD patients compared to patients with normal renal function. LAAO with ACP offers a dramatic reduction of stroke + TIA rate and of bleeding rate persistent in all stages of CKD, as compared to the expected annual risk. (C) 2016 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2016.01.003"],["dc.identifier.isi","000371271400099"],["dc.identifier.pmid","26820363"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41114"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","107"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","111"],["dc.bibliographiccitation.volume","220"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Schroeter, Marco Robin"],["dc.date.accessioned","2017-09-07T11:44:37Z"],["dc.date.available","2017-09-07T11:44:37Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Percutaneous mitral valve repair using MitraClip (R) (MC) is a well-established method for a subset of patients with severe mitral regurgitation (MR) and high risk for surgical intervention. Amplatzer (R) Cardiac Plug (ACP) occludes left atrial appendage and allows the discontinuation of oral anticoagulation and prevention of thromboembolic stroke. Due to the need for femoral and transseptal access in both procedures, a single approach could lead to minor risk of further complications and shorter cumulative intervention time. Methods: We systematically analysed all four patients who underwent a combined procedure with MC and ACP in our heart-centre. All procedures were performed under fluoroscopic as well as echocardiographic guidance, and follow-up controls in a midterm period were carried out. Results: In all patients (2 male/female; age 73-88 years), MC (1-2 Clips) and ACP (size 18-28mm) were successfully implanted in one procedure (mean total time: 114 +/- 17 min). At least moderate MR was achieved and two patients had no complications and therefore were discharged early. In a third patient, a dislocation of ACP occurred 2 h after the implantation. The oldest patient developed a respiratory insufficiency due to cardiac decompensation and further complications. Conclusion: A combination of MC and ACP in a single procedure was feasible in this first case series of patients without a significant extension of procedure time. However, it might be important to select patients carefully. The location of optimal transseptal puncture may be challenging in regard to ACP placement, even in experienced hands and subsequent complications can occur. (C) 2016 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2016.06.170"],["dc.identifier.gro","3141615"],["dc.identifier.isi","000381582000019"],["dc.identifier.pmid","27389439"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1456"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: Abbott Vascular; St. Jude Medical"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.eissn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","MitraClip (R) and Amplatzer (R) cardiac plug implantation in a single procedure: A reasonable approach?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e2223225"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","JAMA Network Open"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Rühlmann, Felix"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Mackert, Alma Franziska"],["dc.contributor.author","Engelhardt, Deborah"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Perl, Thorsten"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2022-09-01T09:49:15Z"],["dc.date.available","2022-09-01T09:49:15Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1001/jamanetworkopen.2022.23225"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113381"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","2574-3805"],["dc.title","Incidence, Associated Risk Factors, and Outcomes of Postoperative Arrhythmia After Upper Gastrointestinal Surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Internist"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Czepluch, Frauke S."],["dc.contributor.author","Schwarz, A."],["dc.contributor.author","Tichelbaecker, Tobias"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.date.accessioned","2018-11-07T10:15:50Z"],["dc.date.available","2018-11-07T10:15:50Z"],["dc.date.issued","2016"],["dc.format.extent","S40"],["dc.identifier.isi","000375417500075"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40896"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","1432-1289"],["dc.relation.issn","0020-9554"],["dc.title","The transfemoral Implantation of a 29 mm metal-free Aortic Valve Bioprosthesis in the elderly is associated with longer Procedure times and post interventional higher Flaps-Gradient"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","87"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","92"],["dc.bibliographiccitation.volume","300"],["dc.contributor.author","Kalbacher, Daniel"],["dc.contributor.author","Daubmann, Anne"],["dc.contributor.author","Tigges, Eike"],["dc.contributor.author","Hünlich, Marc"],["dc.contributor.author","Wiese, Sabrina"],["dc.contributor.author","Conradi, Lenard"],["dc.contributor.author","Schirmer, Johannes"],["dc.contributor.author","Beuthner, Bo Eric"],["dc.contributor.author","Reichenspurner, Hermann"],["dc.contributor.author","Wegscheider, Karl"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schäfer, Ulrich"],["dc.contributor.author","Blankenberg, Stefan"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Schillinger, Wolfang"],["dc.contributor.author","Lubos, Edith"],["dc.date.accessioned","2021-04-14T08:27:38Z"],["dc.date.available","2021-04-14T08:27:38Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.ijcard.2019.09.027"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82358"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0167-5273"],["dc.title","Impact of pre- and post-procedural renal dysfunction on long-term outcomes in patients undergoing MitraClip implantation: A retrospective analysis from two German high-volume centres"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1170"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","EuroIntervention"],["dc.bibliographiccitation.lastpage","1179"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Tzikas, Apostolos"],["dc.contributor.author","Shakir, Samera"],["dc.contributor.author","Gafoor, Sameer"],["dc.contributor.author","Omran, Heyder"],["dc.contributor.author","Berti, Sergio"],["dc.contributor.author","Santoro, Gennaro"],["dc.contributor.author","Kefer, Joelle"],["dc.contributor.author","Landmesser, Ulf"],["dc.contributor.author","Nielsen-Kudsk, Jens Erik"],["dc.contributor.author","Cruz-Gonzalez, Ignacio"],["dc.contributor.author","Sievert, Horst"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Kanagaratnam, Prapa"],["dc.contributor.author","Nietlispach, Fabian"],["dc.contributor.author","Aminian, Adel"],["dc.contributor.author","Kasch, Friederike"],["dc.contributor.author","Freixa, Xavier"],["dc.contributor.author","Danna, Paolo"],["dc.contributor.author","Rezzaghi, Marco"],["dc.contributor.author","Vermeersch, Paul"],["dc.contributor.author","Stock, Friederike"],["dc.contributor.author","Stolcova, Miroslava"],["dc.contributor.author","Costa, Marco"],["dc.contributor.author","Ibrahim, Reda"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Meier, Bernhard"],["dc.contributor.author","Park, Jai-Wun"],["dc.date.accessioned","2020-12-10T18:47:48Z"],["dc.date.available","2020-12-10T18:47:48Z"],["dc.date.issued","2016"],["dc.description.abstract","Aims: To investigate the safety, feasibility, and efficacy of left atrial appendage occlusion (LAAO) with the AMPLATZER Cardiac Plug (ACP) for stroke prevention in patients with atrial fibrillation (AF). Methods and results: Data from consecutive patients treated in 22 centres were collected. A total of 1,047 patients were included in the study. Procedural success was 97.3%. There were 52 (4.97%) periprocedural major adverse events. Follow-up was complete in 1,001/1,019 (98.2%) of successfully implanted patients (average 13 months, total 1,349 patient-years). One-year all-cause mortality was 4.2%. No death at follow-up was reported as device-related. There were nine strokes (0.9%) and nine transient ischaemic attacks (0.9%) during follow-up. The annual rate of systemic thromboembolism was 2.3% (31/1,349 patient-years), which is a 59% risk reduction. There were 15 major bleedings (1.5%) during follow-up. The annual rate of major bleeding was 2.1% (28/1,349 patient-years), which is a 61% risk reduction. Patients with single LAAO on aspirin monotherapy or no therapy and longer follow-up had fewer cerebral and fewer bleeding events. Conclusions: In this multicentre study, LAAO with the ACP showed high procedural success and a favourable outcome for the prevention of AF-related thromboembolism. Modification in antithrombotic therapy after LAAO may result in reduction of bleeding events."],["dc.identifier.doi","10.4244/EIJY15M01_06"],["dc.identifier.isi","000372767000017"],["dc.identifier.issn","1774-024X"],["dc.identifier.pmid","25604089"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78893"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Europa Edition"],["dc.relation.issn","1969-6213"],["dc.relation.issn","1774-024X"],["dc.title","Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","281"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","The Journal of heart valve disease"],["dc.bibliographiccitation.lastpage","288"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Czepluch, Frauke S."],["dc.contributor.author","Schwarz, Alexander"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.date.accessioned","2017-10-27T11:17:58Z"],["dc.date.available","2017-10-27T11:17:58Z"],["dc.date.issued","2016"],["dc.description.abstract","The Direct Flow Medical (DFM) valve is a new non-metallic and repositionable bioprosthesis used for transcatheter aortic valve implantation (TAVI). The study aim was to investigate procedural and post-implant valve data in patients receiving differently sized DFM bioprostheses."],["dc.identifier.fs","623793"],["dc.identifier.pmid","27989037"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/9886"],["dc.language.iso","en"],["dc.notes.status","fcwi"],["dc.title","Predictors of High Post-Procedural Gradients after Catheter-Based Aortic Valve Implantation Using Direct Flow Medical Bioprostheses"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3437"],["dc.bibliographiccitation.issue","36"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","3447"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Willems, Rik"],["dc.contributor.author","Lubinski, Andrzej"],["dc.contributor.author","Bauer, Axel"],["dc.contributor.author","Brugada, Josep"],["dc.contributor.author","Conen, David"],["dc.contributor.author","Flevari, Panagiota"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Harden, Markus"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Lüthje, Lars"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Harden, Markus"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.authorgroup","EU-CERT-ICD Study Investigators"],["dc.date.accessioned","2020-05-07T07:50:46Z"],["dc.date.accessioned","2021-10-27T13:22:10Z"],["dc.date.available","2020-05-07T07:50:46Z"],["dc.date.available","2021-10-27T13:22:10Z"],["dc.date.issued","2020"],["dc.description.abstract","Aims: The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy. Methods and results: We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3%/years annualized mortality, 5.6%/years in the ICD group vs. 9.2%/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95% confidence interval (CI) 0.537–0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class

[["dc.bibliographiccitation.artnumber","e0186387"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PloS one"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Kessel, Barbora"],["dc.contributor.author","Lüthje, Lars"],["dc.contributor.author","Fischer, Thomas H."],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zabel, Markus"],["dc.date.accessioned","2019-07-09T11:44:37Z"],["dc.date.available","2019-07-09T11:44:37Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: There is evidence that the benefit of a primary prophylactic ICD therapy is not equal in all patients. PURPOSE: To evaluate risk factors of appropriate shocks and all- cause mortality in patients with a primary prophylactic ICD regarding contemporary studies. DATA SOURCE: PubMed, LIVIVO, Cochrane CENTRAL between 2010 and 2016. STUDY SELECTION: Studies were eligible if at least one of the endpoints of interest were reported. DATA EXTRACTION: All abstracts were independently reviewed by at least two authors. The full text of all selected studies was then analysed in detail. DATA SYNTHESIS: Our search strategy retrieved 608 abstracts. After exclusion of unsuitable studies, 36 papers with a total patient number of 47282 were included in our analysis. All-cause mortality was significantly associated with increasing age (HR 1.41, CI 1.29-1.53), left ventricular function (LVEF; HR 1.21, CI 1.14-1.29), ischemic cardiomyopathy (ICM; HR 1.37, CI 1.14-1.66) and co-morbidities such as impaired renal function (HR 2.30, CI 1.97-2.69). Although, younger age (HR 0.96, CI 0.85-1.09), impaired LVEF (HR 1.26, CI 0.89-1.78) and ischemic cardiomyopathy (HR 2.22, CI 0.83-5.93) were associated with a higher risk of appropriate shocks, none of these factors reached statistical significance. LIMITATIONS: Individual patient data were not available for most studies. CONCLUSION: In this meta-analysis of contemporary clinical studies, all-cause mortality is predicted by a variety of clinical characteristics including LVEF. On the other hand, the risk of appropriate shocks might be associated with impaired LVEF and ischemic cardiomyopathy. Further prospective studies are required to verify risk factors for appropriate shocks other than LVEF to help select appropriate patients for primary prophylactic ICD-therapy."],["dc.identifier.doi","10.1371/journal.pone.0186387"],["dc.identifier.pmid","29040341"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14842"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59051"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation","info:eu-repo/grantAgreement/EC/FP7/602299/EU//EU-CERT-ICD"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.subject.mesh","Age Factors"],["dc.subject.mesh","Aged"],["dc.subject.mesh","Cardiomyopathy, Dilated"],["dc.subject.mesh","Death, Sudden, Cardiac"],["dc.subject.mesh","Defibrillators, Implantable"],["dc.subject.mesh","Female"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Male"],["dc.subject.mesh","Middle Aged"],["dc.subject.mesh","Myocardial Ischemia"],["dc.subject.mesh","Primary Prevention"],["dc.subject.mesh","Prognosis"],["dc.subject.mesh","Prospective Studies"],["dc.subject.mesh","Risk Factors"],["dc.subject.mesh","Survival Analysis"],["dc.subject.mesh","Ventricular Function, Left"],["dc.title","Predictors of mortality and ICD shock therapy in primary prophylactic ICD patients-A systematic review and meta-analysis."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1836"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","The American Journal of Cardiology"],["dc.bibliographiccitation.lastpage","1841"],["dc.bibliographiccitation.volume","118"],["dc.contributor.author","Freixa, Xavier"],["dc.contributor.author","Llull, Laura"],["dc.contributor.author","Gafoor, Sameer"],["dc.contributor.author","Cruz-Gonzalez, Ignacio"],["dc.contributor.author","Shakir, Samera"],["dc.contributor.author","Omran, Heyder"],["dc.contributor.author","Berti, Sergio"],["dc.contributor.author","Santoro, Gennaro"],["dc.contributor.author","Kefer, Joelle"],["dc.contributor.author","Landmesser, Ulf"],["dc.contributor.author","Nielsen-Kudsk, Jens Erik"],["dc.contributor.author","Kanagaratnam, Prapa"],["dc.contributor.author","Nietlispach, Fabian"],["dc.contributor.author","Gloekler, Steffen"],["dc.contributor.author","Aminian, Adel"],["dc.contributor.author","Danna, Paolo"],["dc.contributor.author","Rezzaghi, Marco"],["dc.contributor.author","Stock, Friederike"],["dc.contributor.author","Stolcova, Miroslava"],["dc.contributor.author","Paiva, Luis"],["dc.contributor.author","Costa, Marco"],["dc.contributor.author","Millan, Xavier"],["dc.contributor.author","Ibrahim, Reda"],["dc.contributor.author","Tichelbaecker, Tobias"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Park, Jai-Wun"],["dc.contributor.author","Sievert, Horst"],["dc.contributor.author","Meier, Bernhard"],["dc.contributor.author","Tzikas, Apostolos"],["dc.date.accessioned","2018-11-07T10:04:29Z"],["dc.date.available","2018-11-07T10:04:29Z"],["dc.date.issued","2016"],["dc.description.abstract","Cardioembolic strokes are generally more lethal and disabling than other source of strokes. Data from PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) suggest that strokes after left atrial appendage occlusion (LAAO) with the Watchman device are less disabling than those in the warfarin group. No data assessing the severity of strokes after LAAO with the AMPLATZER Cardiac Plug (ACP) are available. The objective of the study was to evaluate the severity of cerebrovascular events after LAAO with the ACP in a population mostly characterized by an absolute or relative contraindication to oral anticoagulation. Data from the ACP multicenter registry were analyzed. Disabling strokes were defined as those with a modified Rankin score of 3 to 6 at 90 days after the event. A total of 1,047 subjects were included. The mean age and CHADS(2) score were 75 +/- 8 years and 2.8 +/- 1.3, respectively. Procedural success was achieved in 97.3% and 4.9% of the patients presented procedural major adverse events. Clinical follow-up was complete in 98.2% of patients with a median of 13 months. There were 9 strokes (0.9%), 9 transient ischemic attacks (0.9%), and.no intracranial hemorrhages (0%) at follow-up. After excluding 2 patients with pre-LAAO disability, functional assessment showed disabling events in 3 (19%) of the remaining 16. patients. The median time of presentation was 420 days (interquartile range 234 to 671) after LAAO, and 17 patients (94%) were on single-antiplatelet therapy when the event occurred. According to our results, cerebrovascular events after LAAO with the ACP system were infrequent and mostly nondisabling. (C) 2016 Elsevier Inc. All rights reserved."],["dc.description.sponsorship","St. Jude Medical"],["dc.identifier.doi","10.1016/j.amjcard.2016.08.075"],["dc.identifier.isi","000389868400010"],["dc.identifier.pmid","27745964"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38706"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Excerpta Medica Inc-elsevier Science Inc"],["dc.relation.issn","1879-1913"],["dc.relation.issn","0002-9149"],["dc.title","Characterization of Cerebrovascular Events After Left Atrial Appendage Occlusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]